jnj-20240501

0000200406-24-000048.txt : 20240501 0000200406-24-000048.hdr.sgml : 20240501 20240501070025 ACCESSION NUMBER: 0000200406-24-000048 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240501 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240501 DATE AS OF CHANGE: 20240501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1229 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 24900007 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 8-K 1 jnj-20240501.htm 8-K jnj-20240501

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

May 1, 2024

Johnson & Johnson

(Exact name of registrant as specified in its charter)


New Jersey	1-3215	22-1024240
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

(Address of Principal Executive Offices)

Registrant's telephone number, including area code (732) 524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17

CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, Par Value $1.00	JNJ	New York Stock Exchange
0.650% Notes Due May 2024	JNJ24C	New York Stock Exchange
5.50% Notes Due November 2024	JNJ24BP	New York Stock Exchange
1.150% Notes Due November 2028	JNJ28	New York Stock Exchange
1.650% Notes Due May 2035	JNJ35	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On May 1, 2024, Johnson & Johnson issued the attached earnings schedules for the first quarter ended March 31, 2024. These schedules have been amended to reflect the information referenced in Item 7.01

Item 7.01 Regulation FD Disclosure

On May 1, 2024, the Company announced a proposed Plan of Reorganization (the “Proposed Plan”) for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $6.475 billion payable over 25 years (nominal value of approximately $8.4 billion, discounted at a rate of 4.4%). To account for these settlements and the contemplated comprehensive resolution through the Proposed Plan, the Company recorded an incremental charge of approximately $2.7 billion, for a total reserve as of the first fiscal quarter 2024 at a present value of approximately $11 billion (nominal value of approximately $13.7 billion).

The Proposed Plan is a recognized subsequent event and previously reported GAAP net earnings for the fiscal first quarter ended March 31, 2024 is reduced from $5.4 billion to $3.3 billion. Previously reported earnings per share (EPS) for the fiscal first quarter ended March 31, 2024 is reduced from $2.20 to $1.34. There is no impact to previously reported Adjusted Earnings, Adjusted EPS and Adjusted Operational EPS for the fiscal first quarter ended March 31, 2024.

The press release further discussing this announcement is attached below as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.


Exhibit No.			Description of Exhibit
99.1			Condensed Consolidated Statement of Earnings and Non-GAAP Reconciliations for the fiscal first quarter
99.2			Press Release dated May 1, 2024.
104			The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Johnson & Johnson

(Registrant)

Date:

May 1, 2024

By:

/s/ Robert J. Decker, Jr.

Robert J. Decker, Jr.
Controller
(Principal Accounting Officer)

EX-99.1 2 a2024q1exhibit9912.htm EX-99.1 Document

Exhibit 99.1


Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	FIRST QUARTER

	2024				2023				Percent
				Percent				Percent	Increase
	Amount			to Sales	Amount			to Sales	(Decrease)
Sales to customers	$	21,383		100.0	$	20,894		100.0	2.3
Cost of products sold	6,511			30.4	6,687			32.0	(2.6)
Gross Profit	14,872			69.6	14,207			68.0	4.7
Selling, marketing and administrative expenses	5,257			24.6	4,906			23.5	7.2
Research and development expense	3,542			16.6	3,455			16.6	2.5
In-process research and development impairments	—			—	49			0.2
Interest (income) expense, net	(209)			(1.0)	14			0.1
Other (income) expense, net	2,404			11.2	6,940			33.2
Restructuring	164			0.8	130			0.6
Earnings/(loss) before provision for taxes on income	3,714			17.4	(1,287)			(6.2)
Provision for/(Benefit from) taxes on income	459			2.2	(796)			(3.9)
Net earnings/(loss) from Continuing Operations	$	3,255		15.2	$	(491)		(2.3)
Net earnings from Discontinued Operations, net of tax	—				423
Net earnings/(loss)	$	3,255			$	(68)

Net earnings (loss) per share (Diluted/Basic) from Continuing Operations	$	1.34			$	(0.19)
Net earnings per share (Diluted) from Discontinued Operations	$	—			$	0.16

Average shares outstanding (Diluted/Basic)	2,430.1				2,605.5		*

Effective tax rate from Continuing Operations	12.4		%		61.8		%

Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income from Continuing Operations	$	7,877		36.8	$	7,536		36.1	4.5
Net earnings from Continuing Operations	$	6,580		30.8	$	6,340		30.3	3.8
Net earnings per share (Diluted) from Continuing Operations	$	2.71			$	2.41			12.4
Average shares outstanding (Diluted)	2,430.1				2,634.3
Effective tax rate from Continuing Operations	16.5		%		15.9		%

*Basic shares are used to calculate loss per share in the first quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive
(1) See Reconciliation of Non-GAAP Financial Measures.

(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings from continuing operations before provision for taxes on income," "adjusted net earnings from continuing operations," "adjusted net earnings per share (diluted) from continuing operations," and "adjusted effective tax rate from continuing operations" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations prepared in accordance with GAAP, adjusted earnings from continuing operations before provision for taxes on income, adjusted net earnings from continuing operations, adjusted net earnings per share (diluted) from continuing operations, and adjusted effective tax rate from continuing operations may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.


Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

		First Quarter
	(Dollars in Millions Except Per Share Data)	2024		2023
	Net Earnings/(Loss) from Continuing Operations, after tax- as reported	$	3,255	$	(491)

	Pre-tax Adjustments
	Litigation related	2,726		6,900
	Intangible Asset Amortization expense	1,078		1,122
	COVID-19 Vaccine related costs 1	9		444
	Restructuring related 2	171		130
	Medical Device Regulation 3	51		64
	Acquisition, integration and divestiture related	148		42
	(Gains)/losses on securities	(20)		72
	IPR&D impairments	—		49

	Tax Adjustments
	Tax impact on special item adjustments 4	(856)		(1,980)
	Tax legislation and other tax related	18		(12)
	Adjusted Net Earnings from Continuing Operations, after tax	$	6,580	$	6,340
	Average shares outstanding (Diluted)	2,430.1		2,634.3
	Adjusted net earnings per share from Continuing Operations (Diluted)	$	2.71	$	2.41
	Operational adjusted net earnings per share from Continuing Operations (Diluted)	$	2.72

	Notes:
1	COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments.
2	In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expenses of $144 million in the fiscal first quarter of 2024 and $130 million in the fiscal first quarter of 2023 include the termination of partnered and non-partnered program costs and asset impairments. In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $27 million in the fiscal first quarter of 2024 primarily includes costs related to market and product exits.
3	European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which will be completed during 2024.
4	The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.


Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

	First Quarter March 31, 2024 GAAP		Intangible asset amortization	Litigation related	In-process research and development Impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	First Quarter March 31, 2024 Non-GAAP
Cost of products sold	$	6,511	(1,078)			(7)			(20)	(2)		5,404
Selling, marketing and admin expenses	5,257								(4)			5,253
Research and development expense	3,542						(18)		(27)	(7)		3,490
Other (Income) / Expense	2,404			(2,726)			(130)	20				(432)
Restructuring	164					(164)						—
Provision for taxes on income	459		148	627	—	39	38	(7)	9	2	(18)	1,297
Net Earnings from Continuing Operations	$	3,255	930	2,099	—	132	110	(13)	42	7	18	6,580


	First Quarter April 2, 2023 GAAP		Intangible asset amortization	Litigation related	In-process research and development Impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	First Quarter April 2, 2023 Non-GAAP
Cost of products sold	$	6,687	(1,118)						(23)	(206)		5,340
Selling, marketing and admin expenses	4,906								(7)			4,899
Research and development expense	3,455						(16)		(34)	(16)		3,389
Other (Income) / Expense	6,940		(4)	(6,900)			(26)	(72)		(222)		(284)
In-process research and development Impairments	49				(49)							—
Restructuring	130					(130)						—
Provision for/(Benefit from) taxes on income	(796)		177	1,622	11	32	5	16	12	105	12	1,196
Net Earnings/(Loss) from Continuing Operations	$	(491)	945	5,278	38	98	37	56	52	339	(12)	6,340


Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Q1 YTD - Income Before Tax and Research & Development Expense by Segment
(Dollars in Millions)

	Innovative Medicine					MedTech				Unallocated				Worldwide Total
	2024			2023		2024		2023		2024		2023		2024		2023

Reported Income Before Tax by Segment from Continuing Operations	$	4,969		4,402		1,520		1,409		(2,775)		(7,098)		3,714		(1,287)
% to Sales	36.6%			32.8%		19.4%		18.8%		(13.0)%		(34.0)%		17.4	%	(6.2)	%

Intangible asset amortization expense	698			739		380		383		—		—		1,078		1,122

In-process research and development Impairments	—			—		—		49		—		—		—		49

Litigation Related	—			—		—		—		2,726		6,900		2,726		6,900

Loss/(gain) on securities	(55)			38		22		34		13		—		(20)		72

Restructuring related	144			130		27		—		—		—		171		130

Acquisition, integration and divestiture related	47			—		61		42		40		—		148		42

Medical Device Regulation	—			—		51		64		—		—		51		64

COVID-19 Vaccine related costs	9			444		—		—		—		—		9		444

Adjusted Income Before Tax by Segment from Continuing Operations	$	5,812		5,753		2,061		1,981		4		(198)		7,877		7,536
% to Sales	42.9		%	42.9	%	26.4	%	26.5	%	0.0	%	(0.9)	%	36.8	%	36.1	%


As Reported Research and development expense	$	2,896		2,778		646		677						3,542		3,455
% to Sales	21.4		%	20.7	%	8.3	%	9.1	%					16.6	%	16.6	%

EX-99.2 3 a2024q1exhibit9922.htm EX-99.2 Document

Exhibit 99.2


Media contact: media-relations@its.jnj.com						Investor contact: investor-relations@its.jnj.com

For Immediate Release

Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization

The Plan would resolve 99.75% of all pending talc lawsuits against Johnson & Johnson and its affiliates in the United States

NEW BRUNSWICK, N.J. – May 1, 2024 – Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced a proposed Plan of Reorganization (the “Plan”) by its subsidiary, LLT Management LLC ("LLT"), for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation against it and its affiliates in the United States.

“The Plan is the culmination of our consensual resolution strategy that we announced last October,” said Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson. “Since then, the Company has worked with counsel representing the overwhelming majority of talc claimants to bring this litigation to a close, which we expect to do through this plan.”

The Plan enables the Company to resolve its talc litigation:

•The ovarian claims to be resolved by the Plan constitute 99.75% of the pending talc lawsuits against the Company and its affiliates in the United States.

•The remaining pending personal injury lawsuits relate to mesothelioma and will be addressed outside of the Plan. The Company already has resolved 95% of mesothelioma lawsuits filed to date.

•The State consumer protection claims will also be addressed outside the Plan; the Company already has agreements in principle to do so.

•Finally, and for completeness, the Company has also reached an agreement in principle to resolve all talc-related claims against it in the bankruptcy cases filed by suppliers of its talc (Imerys Talc America, Inc., Cyprus Mines Corporation, and their related parties).

The Plan differs significantly from the prior reorganizations filed by LLT:

•The Plan provides for a three-month solicitation period during which ovarian claimants are informed of its terms and will have the opportunity to vote for or against the Plan – an opportunity they were denied in prior bankruptcy cases.

•If 75% of claimants vote in favor of the Plan, a Company subsidiary may file a consensual “prepackaged” Chapter 11 bankruptcy to secure its confirmation.

“Unlike the prior cases, it is the vote of the claimants – and not the conflicting financial incentives of the small minority of plaintiff lawyers who stand to receive excessive legal fees outside of a reorganization – that decides whether the Plan may proceed,” continued Mr. Haas.

The Plan should be readily confirmed, as it is in the best interests of the ovarian claimants:

•The Plan commits the Company to pay ovarian claimants a present value of approximately $6.475 billion to be paid over 25 years, which is a far better recovery than the claimants stand to recover at trial.

•Most ovarian claimants have not recovered and will not recover anything at trial. Indeed, the Company has prevailed in approximately 95% of ovarian cases tried to date, including every ovarian case tried over the last six years. In addition, based upon the historical run rate, it would take decades to litigate the remaining cases, and therefore, most claimants will never have “their day in court.”

•Further, on March 27, 2024, the Judge presiding over the multi-district litigation (MDL) – where 93% of the ovarian claims are filed – agreed to reconsider the scientific validity of the opinions offered by plaintiffs’ experts in a Daubert hearing, pursuant to the rigorous review required by the new Federal Rules of

Evidence 702. If the opinions fail that review, which the Company expects they will, the ovarian claims should be dismissed.

•In light of those risks, counsel representing the overwhelming majority of current ovarian claimants assisted in the development and support the Plan.

The Plan reflects a substantial commitment to resolve the talc claims:

•In its July 2023 decision dismissing LLT’s prior bankruptcy case, the New Jersey Bankruptcy Court stated that the Company and LLT had made “remarkable progress” towards “a fair, efficient and expeditious settlement” for all claimants and “strongly encouraged” the pursuit of a comprehensive resolution through another bankruptcy.

•The Company and LLT followed that directive, and the Plan proposed by LLT, along with the settlement of the mesothelioma, State consumer protection claims, and disputes with Imerys and Cyprus, is the culmination of those efforts.

•To account for these settlements and the comprehensive resolution of the ovarian claims through the Plan, the Company recorded an incremental charge of approximately $2.7 billion in the first quarter of 2024, for a total reserve of approximately $11.0 billion (or $13.7 billion nominal payable over 25 years).

The Company will continue to pursue alternative resolution pathways:

•While solicitation of the Plan is pending, the Company remains firmly committed to pursuing in parallel its other three previously announced pathways toward a final and comprehensive resolution of the talc litigation.

•Those pathways include (i) appealing the dismissal of LLT’s prior bankruptcy; (ii) aggressively litigating in the tort system against those claimants who elect not to settle, including, importantly, proceeding with the Daubert hearing in the MDL; and (iii) pursuing affirmative claims against the “experts” for false and defamatory narratives about the Company’s products, and the plaintiff law firms who have engaged in unethical conduct related to these claims.

The Company stands by the safety of its talc products:

•The Company reiterates that none of the talc-related claims against it have merit. The claims are premised on the allegations that have been rejected by independent experts, as well as governmental and regulatory bodies, for decades. Additional information on the Company’s position and the science supporting the safety of talc is available at www.FactsAboutTalc.com.

“The talc claims asserted against the Company exemplify the egregious impact on U.S. businesses from meritless litigation and extreme judgments obtained by the plaintiffs’ bar through forum shopping, the distortion of scientific literature with junk science, and the unregulated and surreptitious financing of product litigation by financial institutions, including private equity and sovereign wealth funds,” Mr. Haas concluded.

Additional information regarding the Plan can be found here.

Investor Conference Call

Johnson & Johnson will conduct a conference call with investors to discuss the announcement today, May 1st, at 8:00 a.m. ET. You can join via:

Participant Dial-In: 877-869-3847 (U.S.) / 201-689-8261 (International)

Webcast: https://event.webcasts.com/viewer/event.jsp?ei=1669186&tp_key=e4e521f076

A replay will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.

Cautions Concerning Forward-Looking Statement

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the proposed prepackaged Chapter 11 bankruptcy plan. The reader is cautioned not to rely on these forward-looking statements. The information contained in this press release is for informational purposes only

and should not be construed as a commitment by the Company to engage in any specific strategy or course of action. Due to the inherent uncertainty of litigation, the Company cannot predict the timing, ultimate outcome or financial impact of this matter, or any other ongoing or future litigation. The forward-looking statements in this press release are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of LLT Management LLC and/or Johnson & Johnson. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Neither LLT Management LLC nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. The Company expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

EX-101.SCH 4 jnj-20240501.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 jnj-20240501_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 jnj-20240501_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Information [Line Items] Entity Information [Line Items] Document Period End Date Document Period End Date Common Stock, Par Value $1.00 Common Stock [Member] Pre-commencement Tender Offer Pre-commencement Tender Offer Class of Stock [Domain] Class of Stock [Domain] Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code 1.650% Notes Due May 2035 1.650% Notes Due 2035 [Member] 1.650% Notes Due 2035 [Member] Entity Central Index Key Entity Central Index Key Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code 1.150% Notes Due November 2028 1.150% Notes Due 2028 [Member] 1.150% Notes Due 2028 [Member] Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Document Type Document Type 5.50% Notes Due November 2024 5.50% Notes Due 2024 [Member] 5.50% Notes Due 2024 [Member] Amendment Flag Amendment Flag Class of Stock [Axis] Class of Stock [Axis] Entity File Number Entity File Number Entities [Table] Entities [Table] Entity Tax Identification Number Entity Tax Identification Number 0.650% Notes Due May 2024 0.650% Notes Due 2024 [Member] 0.650% Notes Due 2024 [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 7 jnj-20240501_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 logo.jpg begin 644 logo.jpg MB5!.1PT*&@H -24A$4@ E@ Y" 8 #J454* 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Cover

May 01, 2024

Entity Information [Line Items]

Document Type 8-K

Document Period End Date May 01, 2024

Entity Registrant Name Johnson & Johnson

Entity Incorporation, State or Country Code NJ

Entity File Number 1-3215

Entity Tax Identification Number 22-1024240

Entity Address, Address Line One One Johnson & Johnson Plaza

Entity Address, City or Town New Brunswick

Entity Address, State or Province NJ

Entity Address, Postal Zip Code 08933

City Area Code 732)

Local Phone Number 524-0400

Written Communications false

Soliciting Material false

Pre-commencement Tender Offer false

Pre-commencement Issuer Tender Offer false

Entity Emerging Growth Company false

Entity Central Index Key 0000200406

Amendment Flag false

Common Stock, Par Value $1.00

Entity Information [Line Items]

Title of 12(b) Security Common Stock, Par Value $1.00

Trading Symbol JNJ

Security Exchange Name NYSE

0.650% Notes Due May 2024

Entity Information [Line Items]

Title of 12(b) Security 0.650% Notes Due May 2024

Trading Symbol JNJ24C

Security Exchange Name NYSE

5.50% Notes Due November 2024

Entity Information [Line Items]

Title of 12(b) Security 5.50% Notes Due November 2024

Trading Symbol JNJ24BP

Security Exchange Name NYSE

1.150% Notes Due November 2028

Entity Information [Line Items]

Title of 12(b) Security 1.150% Notes Due November 2028

Trading Symbol JNJ28

Security Exchange Name NYSE

1.650% Notes Due May 2035

Entity Information [Line Items]

Title of 12(b) Security 1.650% Notes Due May 2035

Trading Symbol JNJ35

Security Exchange Name NYSE

Cover	May 01, 2024
Entity Information [Line Items]
Document Type	8-K
Document Period End Date	May 01, 2024
Entity Registrant Name	Johnson & Johnson
Entity Incorporation, State or Country Code	NJ
Entity File Number	1-3215
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732)
Local Phone Number	524-0400
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0000200406
Amendment Flag	false
Common Stock, Par Value $1.00
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.650% Notes Due May 2024
Entity Information [Line Items]
Title of 12(b) Security	0.650% Notes Due May 2024
Trading Symbol	JNJ24C
Security Exchange Name	NYSE
5.50% Notes Due November 2024
Entity Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ24BP
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Entity Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ28
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Entity Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ35
Security Exchange Name	NYSE

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 6 22 1 false 5 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.jnj.com/role/Cover Cover Cover 1 false false All Reports Book All Reports jnj-20240501.htm jnj-20240501.xsd jnj-20240501_def.xml jnj-20240501_lab.xml jnj-20240501_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "jnj-20240501.htm": { "nsprefix": "jnj", "nsuri": "http://www.jnj.com/20240501", "dts": { "inline": { "local": [ "jnj-20240501.htm" ] }, "schema": { "local": [ "jnj-20240501.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "jnj-20240501_def.xml" ] }, "labelLink": { "local": [ "jnj-20240501_lab.xml" ] }, "presentationLink": { "local": [ "jnj-20240501_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 4, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 6, "entityCount": 1, "segmentCount": 5, "elementCount": 32, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 34 }, "report": { "R1": { "role": "http://www.jnj.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20240501.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20240501.htm", "first": true, "unique": true } } }, "tag": { "jnj_A0.650NotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20240501", "localname": "A0.650NotesDue2024Member", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "0.650% Notes Due May 2024", "label": "0.650% Notes Due 2024 [Member]", "documentation": "0.650% Notes Due 2024 [Member]" } } }, "auth_ref": [] }, "jnj_A1.150NotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20240501", "localname": "A1.150NotesDue2028Member", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "1.150% Notes Due November 2028", "label": "1.150% Notes Due 2028 [Member]", "documentation": "1.150% Notes Due 2028 [Member]" } } }, "auth_ref": [] }, "jnj_A1.650NotesDue2035Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20240501", "localname": "A1.650NotesDue2035Member", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "1.650% Notes Due May 2035", "label": "1.650% Notes Due 2035 [Member]", "documentation": "1.650% Notes Due 2035 [Member]" } } }, "auth_ref": [] }, "jnj_A5.50NotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20240501", "localname": "A5.50NotesDue2024Member", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "5.50% Notes Due November 2024", "label": "5.50% Notes Due 2024 [Member]", "documentation": "5.50% Notes Due 2024 [Member]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Par Value $1.00", "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.jnj.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0000200406-24-000048-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000200406-24-000048-xbrl.zip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end XML 20 jnj-20240501_htm.xml IDEA: XBRL DOCUMENT 0000200406 2024-05-01 2024-05-01 0000200406 us-gaap:CommonStockMember 2024-05-01 2024-05-01 0000200406 jnj:A0.650NotesDue2024Member 2024-05-01 2024-05-01 0000200406 jnj:A5.50NotesDue2024Member 2024-05-01 2024-05-01 0000200406 jnj:A1.150NotesDue2028Member 2024-05-01 2024-05-01 0000200406 jnj:A1.650NotesDue2035Member 2024-05-01 2024-05-01 0000200406 false 8-K 2024-05-01 Johnson & Johnson NJ 1-3215 22-1024240 One Johnson & Johnson Plaza New Brunswick NJ 08933 732) 524-0400 false false false false Common Stock, Par Value $1.00 JNJ NYSE 0.650% Notes Due May 2024 JNJ24C NYSE 5.50% Notes Due November 2024 JNJ24BP NYSE 1.150% Notes Due November 2028 JNJ28 NYSE 1.650% Notes Due May 2035 JNJ35 NYSE false